“We need to grow”
Why the US AMR accelerator aims to expand its reach in Europe to support antibacterial R&D, and why it is important to bundle global resources, explains Kevin Outterson, Executive Director of CARB-X.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
AstraZeneca partners with Seres Therapeutics
Under a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer immune therapies.
AMR: Snipr Biome Aps raises €43m to programme pathogens for death
Copenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) and Wellington Partners (Munich).
Small-molecule acts as broad-band influenza entry blocker
Researchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
Seventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions.
Numab AG bags CHF70m in licencing deal
Swiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc.
Biogen bags UK company Nightstar for US$877m
Biogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders.
EMA approves eight meds for market
The EMA‘s human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.
Eurofins CDMO: Highly Potent Drug Development from early stage
High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles, and represent a growing area of global development focus, for applications such as oncology and hormone-based treatments. Although this class of molecules offers numerous benefits to patients, they require particular care and attention in ensuring the safety for those involved in their manufacture and handling.
Genfit set to raise $100m in Nasdaq IPO
French Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.